Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
PepsiCo's "Rolling Remembrance" American Flag Relay Puts Veteran Drivers at the Wheel to Raise Funds and Awareness for Children of Fallen Patriots Foundation
Fresh off the company’s IPO at the New York Stock Exchange Bowhead Specialty CEO Stephen Sills discusses what’s next and why some insurance rates are rising.
AAA predicts a surge in summer 2024 travel, with 44 million travelers, surpassing pre-pandemic levels. Expect more solo trips, AI use, and Taylor Swift.
As Americans prepare for a long weekend of grilling, Impossible Foods wants to put aside the culture wars, win over meat eaters – and IPO when it's 'ready.'
In April, grocery prices rose by 1.2 percent, reaching pre-pandemic levels of food inflation. Could an e-commerce grocer be the solution? Thrive Market says yes
